Clinical Trial Update: A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of thalidomide and capecitabine in metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Thalidomide (thalidomide)

Snippet

Sponsor: Stanford University | Conditions: Kidney Neoplasms | Phase 2 | Status: COMPLETED